재조합 백신 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of recombinant vaccines Market

The global recombinant vaccines market is poised for robust growth owing to increasing prevalence of infectious diseases, rising demand for safe and effective vaccines, and strategic investments by leading pharmaceutical companies. The market was valued at USD 41.59 billion in 2025, expected to reach USD 44.86 billion in 2026, and projected to grow to USD 109.06 billion by 2034, reflecting a CAGR of 10.62% during the forecast period.

Recombinant vaccines are genetically engineered vaccines that target specific genes or proteins to elicit a focused immune response. These vaccines offer high specificity, scalability, and safety advantages compared to traditional vaccines. For example, in May 2023, GSK received U.S. FDA approval for Arexvy, a recombinant vaccine for preventing lower respiratory tract disease caused by RSV in adults aged 60 years and older.

The market is dominated by key players such as Bavarian Nordic, GSK plc, Pfizer Inc., and Merck & Co., Inc., whose strong product portfolios and global distribution networks contribute to their leading positions.

Market Dynamics

Market Drivers

One of the major growth drivers is the rising investment in research and development. Recombinant vaccines can be developed without using the entire pathogen, reducing the risk of infection and adverse events. Companies are heavily investing in developing these vaccines to meet growing demand. For instance, in September 2024, the U.S. International Development Finance Corporation (DFC) provided a loan of up to USD 20 million to Panacea Biotec Limited for developing an IPV-based recombinant polio vaccine, EasySix.

Market Restraints

The high cost of vaccine development and risk of clinical trial failures restrict market growth. Production involves advanced cell culture systems, purification processes, and expensive bioreactors, increasing capital expenditure. For example, in August 2023, GSK plc invested USD 270.6 million to expand recombinant vaccine capacity in Belgium. Similarly, in August 2025, the U.S. HHS terminated mRNA vaccine development activities under BARDA due to ineffective protection against certain infections.

Market Opportunities

The development of therapeutic vaccines offers significant opportunities for market expansion. Recombinant vaccines for cancer or viral infections provide targeted therapeutic benefits. In March 2025, ImmunityBio, Inc. partnered with U.S. Urology Partners to expand access for recombinant BCG (rBCG) immunotherapy for bladder cancer. Likewise, in June 2024, Moderna and Merck reported positive Phase 2 data for a personalized recombinant mRNA cancer vaccine in melanoma patients.

Market Challenges

Cold chain logistics and supply challenges remain critical barriers. Recombinant vaccines are temperature-sensitive, requiring strict cold storage to maintain efficacy. Low- and middle-income countries often face infrastructure challenges, restricting vaccine accessibility. For example, in September 2021, the WHO delivered 350 ultra-cold chain freezers to over 45 countries to address these limitations.

Market Trends

A prominent trend is the development of combination vaccines that provide protection against multiple diseases in a single shot, improving compliance and reducing storage challenges. In December 2024, Sanofi received Fast Track designation for combination vaccines targeting influenza and COVID-19 in adults above 50 years.

Segmentation Analysis

By Type:

• Subunit vaccines dominated in 2026 with 77.11% share, driven by high stability, safety, and targeted immune response. For example, India developed ORBEVAXTM, a protein subunit COVID-19 vaccine, under the Mission COVID Suraksha initiative.
• Vector-based vaccines are also gaining traction but represent a smaller share.

By Disease Indication:

• HPV vaccines led in 2026 with 38.29% share, supported by rising disease prevalence and expanded production capacities. Merck & Co., Inc. expanded its Elkton, Virginia facility in April 2022 for HPV vaccine supply.
• Hepatitis B vaccines are projected to grow at a 15.1% CAGR during the forecast period.

By Route of Administration:

• Parenteral vaccines dominated in 2026 with 78.38% share, due to greater bioavailability and site-specific action. For instance, Valneva SE received FDA approval in November 2023 for Ixchiq, the first parenteral chikungunya vaccine.
• Oral vaccines are expected to grow at a significant rate.

By Distribution Channel:

• Government suppliers dominated in 2024, facilitating routine vaccination programs, especially in low- and middle-income regions.
• Hospitals and retail pharmacies held 60.89% share in 2026. Strategic collaborations, such as Merck's partnership with Gavi and UNICEF to supply 115 million HPV vaccine doses by 2025, further strengthened this channel.

Regional Outlook

• North America dominated with USD 17.75 billion in 2025, growing to USD 19.22 billion in 2026, driven by advanced healthcare infrastructure and high vaccine adoption.
• Europe was valued at USD 8.11 billion in 2025, with projected strong growth (8.68% CAGR). The UK and Germany markets are expected to reach USD 1.73 billion and USD 2.11 billion by 2026, respectively.
• Asia Pacific reached USD 9.74 billion in 2025, with Japan, China, and India markets projected at USD 1.61 billion, 2.53 billion, and 2.23 billion by 2026, respectively.
• Latin America recorded USD 2.09 billion in 2025, while Middle East & Africa (GCC) stood at USD 0.18 billion in 2025, with moderate growth expected.

Competitive Landscape

The market is semi-consolidated, dominated by Bavarian Nordic, GSK plc, Pfizer Inc., and Merck & Co., Inc.. Other players include Mitsubishi Chemical, AstraZeneca, Sanofi, EMERGENT, and BIKEN, focusing on product innovation, strategic partnerships, and geographic expansion.

Key Developments:

• July 2025: GSK approved prefilled syringe of Shingrix (zoster vaccine).
• April 2025: GC Biopharma approved for anthrax vaccine BARYTHRAX in South Korea.
• March 2024: IIT Guwahati launched recombinant vaccine for Swine Fever Virus.
• May 2023: Pfizer received FDA approval for ABRYSVO (RSV vaccine).

Conclusion

The global recombinant vaccines market is projected to grow from USD 41.59 billion in 2025 to USD 109.06 billion by 2034, at a CAGR of 10.62%. Growth is driven by rising infectious disease prevalence, investments in R&D, development of subunit and combination vaccines, and expansion of therapeutic applications. Despite challenges such as high manufacturing costs and cold chain logistics, opportunities in HPV, hepatitis B, and therapeutic cancer vaccines, along with strategic collaborations, will continue to propel market expansion globally.

Segmentation By Type

• Subunit Vaccines
• Vector-Based Vaccines

By Disease Indication

• HPV
• Herpes Zoster
• Hepatitis B
• Others

By Route of Administration

• Parenteral
• Others

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Region

• North America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of Key Diseases, By Key Countries/ Region, 2025
• 4.2. Regulatory Scenario by Key Countries/ Region, 2025
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Technological Advancements in the Vaccines Market
• 4.5. New Product Launches, By Key Players
• 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Subunit Vaccines
  • 5.1.2. Vector-Based Vaccines
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Human Papillomavirus (HPV)
  • 5.2.2. Herpes Zoster
  • 5.2.3. Hepatitis B
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital & Retail Pharmacies
  • 5.4.2. Government Suppliers
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Subunit Vaccines
  • 6.1.2. Vector-Based Vaccines
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Human Papillomavirus (HPV)
  • 6.2.2. Herpes Zoster
  • 6.2.3. Hepatitis B
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital & Retail Pharmacies
  • 6.4.2. Government Suppliers
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Subunit Vaccines
  • 7.1.2. Vector-Based Vaccines
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Human Papillomavirus (HPV)
  • 7.2.2. Herpes Zoster
  • 7.2.3. Hepatitis B
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital & Retail Pharmacies
  • 7.4.2. Government Suppliers
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Subunit Vaccines
  • 8.1.2. Vector-Based Vaccines
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Human Papillomavirus (HPV)
  • 8.2.2. Herpes Zoster
  • 8.2.3. Hepatitis B
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital & Retail Pharmacies
  • 8.4.2. Government Suppliers
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Subunit Vaccines
  • 9.1.2. Vector-Based Vaccines
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Human Papillomavirus (HPV)
  • 9.2.2. Herpes Zoster
  • 9.2.3. Hepatitis B
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital & Retail Pharmacies
  • 9.4.2. Government Suppliers
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Subunit Vaccines
  • 10.1.2. Vector-Based Vaccines
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Human Papillomavirus (HPV)
  • 10.2.2. Herpes Zoster
  • 10.2.3. Hepatitis B
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital & Retail Pharmacies
  • 10.4.2. Government Suppliers
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  • 11.2.1. Bavarian Nordic
  • 11.2.2. GSK plc
  • 11.2.3. Pfizer Inc.
  • 11.2.4. Merck & Co., Inc.
  • 11.2.5. CSL
  • 11.2.6. Mitsubishi Chemical Group Corporation
  • 11.2.7. AstraZeneca
  • 11.2.8. Sanofi
  • 11.2.9. EMERGENT
  • 11.2.10. BIKEN.